Daily Archives: October 6, 2022

First patient treated in Clarity’s therapeutic prostate cancer trial

Sydney, Australia 7 October 2022 Highlights Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)1 investigating Targeted Copper Theranostics (TCTs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) Data from the initial dosimetry phase with 64Cu SAR-bisPSMA was assessed by the Safety Review Committee…

First participant imaged in Phase II SAR-Bombesin prostate cancer trial in the US

Sydney, Australia 6 October 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has successfully imaged its first participant in the US-based diagnostic 64Cu SAR-Bombesin trial (SABRE NCT05407311)1 for patients with PSMA-negative…